mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
Tóm tắt
Từ khóa
Tài liệu tham khảo
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
Tracking SARS-CoV-2 variants (World Health Organization, accessed 5 June 2021); https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
Abu-Raddad, L. J., Chemaitelly, H., Butt, A. A. & National Study Group for Covid-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. https://pubmed.ncbi.nlm.nih.gov/33951357/ (2021).
Abu-Raddad, L. J. et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Sci. Rep. 11, 6233 (2021).
Qatar Monthly Statistics (Planning and Statistics Authority, accessed 26 May 2020); https://www.psa.gov.qa/en/pages/default.aspx
Vogels, C., Fauver, J. & Grubaugh, N. Multiplexed RT–qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern V.3. https://doi.org/10.17504/protocols.io.br9vm966 (2021).
National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar viral genome sequencing data. Data on randomly collected samples between February 1–May 10, 2021 (Ministry of Public Health, 2021).
Bertollini, R. et al. Associations of vaccination and of prior infection with positive PCR test results for SARS-CoV-2 in airline passengers arriving in Qatar. JAMA https://pubmed.ncbi.nlm.nih.gov/34106201/ (2021).
Lopez Bernal, J. et al. Effectiveness of the Pfizer–BioNTech and Oxford–AstraZeneca vaccines on Covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. Brit. Med. J. 373, n1088 (2021).
Voysey, M. et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet 397, 881–891 (2021).
Abu-Raddad, L. J. et al. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J. Travel Med. https://pubmed.ncbi.nlm.nih.gov/34050372/ (2021).
Seedat, S. et al. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates. Preprint at https://www.medrxiv.org/content/10.1101/2020.11.29.20240416v1.full (2020).
Hitchings, M. D. T. et al. Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: a test-negative case-control study. Preprint at https://www.medrxiv.org/content/10.1101/2021.04.07.21255081v1 (2021).
Hunter, P. R. & Brainard, J. Estimating the effectiveness of the Pfizer COVID-19 BNT162b2 vaccine after a single dose. A reanalysis of a study of ‘real-world’ vaccination outcomes from Israel. Preprint at https://www.medrxiv.org/content/10.1101/2021.02.01.21250957v1 (2021).
Hall, V. J. et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet 397, 1725–1735 (2021).
Daum, R. S., Siber, G. R., Ballanco, G. A. & Sood, S. K. Serum anticapsular antibody response in the first week after immunization of adults and infants with the Haemophilus influenzae type b-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J. Infect. Dis. 164, 1154–1159 (1991).
Jackson, M. L. & Nelson, J. C. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 31, 2165–2168 (2013).
Verani, J. R. et al. Case-control vaccine effectiveness studies: preparation, design, and enrollment of cases and controls. Vaccine 35, 3295–3302 (2017).
Thermo Fisher Scientific. TaqPath™ COVID‑19 CE‑IVD RT‑PCR Kit instructions for use (Thermo Fisher Scientific, accessed 2 December 2020); https://assets.thermofisher.com/TFS-Assets/LSG/manuals/MAN0019215_TaqPathCOVID-19_CE-IVD_RT-PCR%20Kit_IFU.pdf
Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom (ECDC, accessed 10 February 2021); https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf
Galloway, S. E. et al. Emergence of SARS-CoV-2 B.1.1.7 Lineage – United States, December 29, 2020–January 12, 2021. MMWR Morb. Mortal. Wkly Rep. 70, 95–99 (2021).
Challen, R. et al. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. Brit. Med. J. 372, n579 (2021).
COVID-19 clinical management: living guidance (WHO, accessed 15 May 2021); https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1
International guidelines for certification and classification (coding) of COVID-19 as cause of death (WHO, accessed 15 May 2021); https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19-20200420-EN.pdf?ua=1
Al-Thani, M. H. et al. SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar. Open Forum Infect. Dis. May 2, ofab221 (2021).
Jeremijenko, A. et al. Herd Immunity against severe acute respiratory syndrome coronavirus 2 infection in 10 communities, Qatar. Emerg. Infect. Dis. 27, 1343–1352 (2021).
Coyle, P. V. et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: an analysis of antibody testing on a sample of 112,941 individuals. iScience 24, 102646 (2021).
Kalikiri, M. K. R. et al. High-throughput extraction of SARS-CoV-2 RNA from nasopharyngeal swabs using solid-phase reverse immobilization beads. Preprint at https://www.medrxiv.org/content/10.1101/2020.04.08.20055731v1 (2020).
Kubina, R. & Dziedzic, A. Molecular and serological tests for COVID-19 a comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics. Diagnostics (Basel) 10, 434 (2020).
Cobas® SARS-CoV-2: qualitative assay for use on the cobas® 6800/8800 Systems (US FDA, accessed 2 December 2020); https://www.fda.gov/media/136049/download
Jacoby, P. & Kelly, H. Is it necessary to adjust for calendar time in a test negative design? Responding to: Jackson ML, Nelson JC. The test negative design for estimating influenza vaccine effectiveness. Vaccine 2013;31, 2165–8. Vaccine 32, 2942 (2014).
Rothman, K. J., Greenland, S. & Lash, T. L. Modern Epidemiology (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008).
Abu-Raddad, L. J. et al. Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting. Clin. Infect. Dis. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1846/6033728 (2020).
Abu-Raddad, L. J. et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. EClinicalMedicine 35, 100861 (2021).
Statistical Software: Release 16.1 (StataCorp, 2019); https://www.stata.com